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Background: The assessment of symptoms of chronic obstructive pulmonary disease (COPD) is important for
monitoring and managing the disease and for evaluating outcomes of interventions. COPD patients experience
symptoms during the day and night, and symptoms experienced at night often disturb sleep. The aim of this paper
is to describe methods used to develop a patient-reported outcome (PRO) instrument for evaluating nighttime
symptoms of COPD, and to document evidence for the content validity of the instrument.
Methods: Literature review and clinician interviews were conducted to inform discussion guides to explore
patients’ nighttime COPD symptom experience. Data from focus groups with COPD patients was used to develop a
conceptual framework and the content of a new PRO instrument. Patient understanding of the new instrument
was assessed via cognitive interviews with COPD patients.
Results: The literature review confirmed that there is no instrument with evidence of content validity currently
available to assess nighttime symptoms of COPD. Additionally, the literature review and clinician interviews
suggested the need to understand patients’ experience of specific symptoms in order to evaluate nighttime
symptoms of COPD. Analyses of patient focus group data (N = 27) supported saturation of concepts and aided in
development of a conceptual framework. Items were generated using patients’ terminology to collect data on
concepts in the framework including the occurrence and severity of COPD symptoms, use of rescue medication at
night, and nocturnal awakening. Response options were chosen to reflect concepts that were salient to patients.
Subsequent cognitive interviewing with ten COPD patients demonstrated that the items, response options, recall
period, and instructions were understandable, relevant, and interpreted as intended.
Conclusions: A new PRO instrument, the Nighttime Symptoms of COPD Instrument (NiSCI), was developed with
documented evidence of content validity. The NiSCI is ready for empirical testing, including item reduction and
evaluation of psychometric properties.
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Chronic obstructive pulmonary disease (COPD) is de-
fined by persistent airflow limitation that is usually pro-
gressive and is associated with an enhanced chronic
inflammatory response in the airways and the lungs to
noxious particles or gases [1]. These changes result in
breathlessness and other respiratory symptoms such as
cough, sputum production, wheezing and chest tight-
ness, which are associated with impaired quality of life
of COPD patients [2]. In particular, sleep disturbances
among patients with COPD have been linked to negative
outcomes, underscoring the importance of both measur-
ing and reducing sleep disturbance [3]. For instance, pa-
tients experience circadian variation in lung function
and COPD symptoms occurring in the evening which
may be particularly bothersome to patients due to their
impact on sleep [3]. Similarly, a recent Internet survey
showed that nighttime symptoms are common among
patients with COPD, with 25% of patients indicating that
their symptoms at night were worse than usual. Further,
the experience of symptoms at night was even more pro-
nounced among the subgroup of patients with severe
COPD, with 34% reporting a worsening of symptoms at
night [4].
Reducing symptom severity is a key target for the clin-
ical management of COPD and recent guidelines en-
courage the use of validated questionnaires to assess
COPD symptoms [1,5]. Only a few clinical trials for
COPD maintenance therapies have specifically evaluated
the benefit of treatment on nighttime symptoms of
COPD, using methods such as daily diaries to record
nighttime awakenings [6-10] and nighttime use of rescue
medications [10,11]. However, there is currently no stan-
dardized approach to doing so.
In recent years, regulatory agencies have increased
their scrutiny of patient-reported outcome (PRO) mea-
sures. In particular, the United Stated Food and Drug
Administration (FDA) released the “Guidance for Indus-
try on Patient-Reported Outcome Measures: Use in
Medical Product Development to Support Labeling
Claims,” which emphasizes the need to demonstrate an
instrument’s content validity [12]. Achieving content val-
idity requires concept elicitation from patients using
qualitative methods; specifically, focus groups or individ-
ual patient interviews. Additionally, evidence of patient
understanding of a measure is also important to ensure
content validity [13,14]. This evidence is usually col-
lected using cognitive interviewing following the com-
pletion of an initial draft of the instrument (initial draft
referred to as Version 1 in this manuscript).
The aim of the present study was to develop a new
PRO measure in accordance with the current FDA PRO
Guidance [12], that could be used in clinical trials to
support label claims pertaining to the benefit oftreatments for nighttime symptoms of COPD (e.g., re-
duction of nighttime symptoms). This manuscript out-
lines the first phase of work done for concept elicitation
to develop the content and format of the instrument and
cognitive interviewing to test patients’ understanding of
the new instrument, using methods outlined by the
International Society of Pharmacoeconomic and Out-
comes Research (ISPOR) PRO Good Research Practices
Task Force [13,14].
Methods
Concept elicitation: literature review and clinician
interviews
The research team conducted a review of the respiratory
literature through EMBASE and MEDLINE databases
(2000–2009), abstracts from the American College of
Chest Physicians (2003–2008), the American Thoracic
Society (2008–2009), and the European Respiratory Soci-
ety (2005–2008). Information collected included articles
and abstracts about: a) clinical trials which measured
nighttime COPD symptoms, b) non-clinical trial litera-
ture that contained discussion of nighttime symptoms of
COPD, and c) literature on other instruments measuring
nighttime symptoms of COPD. Interviews with clinicians
were also conducted in order to determine the clinical
context of evaluating the benefit of treatment on night-
time symptoms of COPD. Information from this phase
of the project was used to draft a framework for explor-
ing patient experiences of nighttime COPD symptoms
on which the subsequent instrument development work
was based.
Concept elicitation: focus group discussions
Focus group discussions were conducted to obtain infor-
mation directly from COPD patients about the most im-
portant concepts related to the experience of COPD
symptoms at night. A discussion guide was developed
for the focus groups based on the conceptual framework
resulting from the literature review and clinician inter-
views. The study protocol developed for concept elicit-
ation (Version 3.0 dated 23rd December 2009) and
cognitive interviews (Version 4.0 dated 4th September
2010) was reviewed and approved by a human subjects
institutional review board (IRB).
Focus group participants were recruited from out-
patient clinic sites in four different locations in the
United States: Virginia, New York, North Carolina, and
Texas. First, site staff were trained on the study protocol.
Then, clinical research coordinators at the sites reviewed
patient charts to determine potential patient eligibility.
The research coordinators were provided with a screen-
ing script to introduce patients to the study, and were
instructed to strive for representativeness among
recruited patients that would be comparable to that of
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der, age, ethnic diversity, and COPD severity. After pa-
tients reviewed the IRB-approved information about
the study and provided written informed consent, re-
search coordinators completed forms to document each
patient’s eligibility and to capture information on clin-
ical characteristics.
Focus group participants were selected to match the
target population of future clinical trials assessing im-
provement in nighttime symptoms of COPD. Eligibility
criteria for the focus groups were determined based on
recommendations from clinical expert interviews. Thus,
to be included in the study, focus group participants
were required to have experienced COPD symptoms at
night and/or the early morning for at least three nights/
days a week, be 40 years of age or older, be a current or
former cigarette smoker with a smoking history of at
least ten pack-years, and have a current medical diagno-
sis of COPD (including chronic bronchitis and/or
emphysema).
Participants were excluded from the study if they had
experienced a COPD exacerbation or unexpected visit to
the clinic, ER, or hospital and/or used prescription
medication to treat an exacerbation within six weeks
prior to eligibility assessment; used narcotics, sleep aids,
sedating antihistamines, sedatives, monoamine oxidase
inhibitors (MAOIs), or other medications known to
affect daytime somnolence or sleep quality (as assessed
by site clinical research coordinators); did not maintain
regular day/night waking/sleeping cycles (e.g., night shift
workers); chronically used oxygen therapy ≥15 hours/
day; had a Body Mass Index (BMI) of 35 or above; or
had a diagnosis of asthma, sleep apnea, or experienced
nocturnal symptoms of gastroesophageal reflux disease
(GERD) that were not controlled by treatment.
Focus group discussions were led by trained and expe-
rienced moderators who used a semi-structured inter-
view guide designed to facilitate discussion and create
consistency across sessions. A trained research assistant
was also present during focus groups to take notes and
assist with the session. Moderators elicited information
from participants regarding their experiences of night-
time symptoms of COPD, using open-ended questions.
After each focus group, the research team reviewed the
notes taken and the adequacy of the interview guide and
revised it to enhance data collection, if needed.
At the close of the focus group discussions, each par-
ticipant completed health status and sociodemographic
questionnaires, including the St. George’s Respiratory
Questionnaire for COPD Patients (SGRQ-C) [15,16] and
the Hospital Anxiety and Depression Scale (HADS)
[17,18]. Each session (focus group discussion and ques-
tionnaire completion) lasted approximately 1.5 hours,
and was audio-recorded and transcribed for analysis.Analysis of focus group discussions
A phenomenological approach was used to analyze tran-
scripts of the audio-recordings, based on grounded the-
ory, which refers to the inductive process of identifying
analytical categories as they emerge from the data
[19,20]. The analysis involved open, axial, and selective
coding, and the phenomenological approach aimed to
understand patient experiences of COPD symptoms at
nighttime. This process is an emergent methodology that
aids hypothesis generation and allows the researcher to
uncover key concepts and insights from the data.
A coding dictionary was developed by examining tran-
script data for themes and subthemes. To begin, two re-
searchers independently reviewed and coded one of the
four transcripts. The two researchers met to discuss
inter-rater agreement and refined the coding approach
and dictionary for use in examining the remaining three
transcripts. Each of the three remaining transcripts was
coded independently by the two researchers, after which,
the two researchers reviewed their findings. The re-
searchers discussed disagreements and reconciled any
divergent codes to determine the final coding assessment
across all four transcripts. An iterative process was used
to identify analytical categories, and to analyze the data
to uncover key concepts and insights until no new codes
or coding groups were required; i.e., until all text from
the transcripts had been assigned to one or more codes.
Focus group data were analyzed with the assistance of
ATLAS.ti (version 5.0) software [21]. Data from ques-
tionnaires were summarized using descriptive statistics.
Conceptual framework
Concepts emerging from the focus group discussions
were tracked on tables following each discussion, to
monitor saturation. Saturation was defined as the point
where themes from prior discussions were echoed in
later discussions and no new themes were introduced
beyond those previously identified. An analysis of the
data from the concept elicitation work with patients
confirmed saturation of concepts. Subsequently, the ini-
tial framework of concepts identified from the literature
and clinician interviews was refined into a conceptual
framework for a new PRO instrument.
Item generation
Items were developed for Version 1 of the measure to
collect information about all concepts in the revised
conceptual framework. The authors used an iterative
process of drafting, evaluation, and revision to generate
the items, response options, instructions, and recall
period for the instrument. Item stems and response op-
tions were generated to reflect the terminology used by
patients. Recall period was selected to best capture the
full variability of the concepts.
Hareendran et al. Health and Quality of Life Outcomes 2013, 11:104 Page 4 of 9
http://www.hqlo.com/content/11/1/104The initial item pool was reviewed by an expert in cul-
tural and linguistic translation. To create Version 1,
grammatical edits and minor changes in wording were
made to ensure readability and facilitate consistency in
words and meaning across translations.
Confirmation of content validity: cognitive interviews
Following development of the item pool, the items were
formatted as Version 1 of the PRO instrument, adminis-
tered to patients, and tested in one-on-one cognitive in-
terviews to further confirm the content validity of the
instrument. Cognitive interviews were conducted to as-
sess the respondents’ understanding of the questionnaire
and its items, in relation to the intended meaning and to
evaluate comprehensiveness of the content to evaluate
the target concept [14]. Recruitment was from a single
clinical research office, and followed the same recruit-
ment process used for focus groups. The study protocol
was reviewed and approved by an IRB. Informed consent
was obtained from each participant prior to discussion
of study-related materials. Inclusion and exclusion cri-
teria were the same as for the focus groups, with the ex-
ception that participants in the cognitive interviews
could not have participated in the earlier focus group
discussions.
Trained and experienced interviewers administered
Version 1 of the Nighttime Symptoms of COPD Instru-
ment (NiSCI) and conducted interviews using a semi-
structured interview guide. The administration of Ver-
sion 1 of the NiSCI for cognitive interviewing was
designed to mimic the format that would be used in
clinical trials.
Patients were included in two rounds of cognitive
interviewing. Following interviews with the first set of
participants, the results and the interview guide were
reviewed. Minor alterations to the instrument were
made based on patient feedback and the interview guide
was refined for clarity. Revisions were based on partici-
pant comments, and consideration was also given to
data gathered during concept elicitation focus groups.
The remaining participants completed the revised in-
strument (Version 2) and were interviewed using the
updated interview guide.
During cognitive interviews, patients’ comprehension
of the instrument and the comprehensiveness of the
items were assessed, and patients were asked to provide
feedback on the instrument’s instructions, as well as
the appropriateness of the recall period and response
options. To evaluate patient understanding, interviews
were conducted with attention to verbal and non-
verbal cues from the participants. At the end of
the interview, patients completed the SGRQ, HADS,
and a sociodemographic questionnaire. Interviews were
audio-recorded and transcribed for analysis.Analysis of cognitive interviews
Qualitative analysis software (ATLAS.ti version 5.0) [21]
was used to analyze the transcripts of the audio-
recordings, as it organized participant responses to each of
the items. Similar to the process used to analyze the data
from concept elicitation interviews, coders discussed and
revised the coding schemes and definitions throughout
the analysis process, until all text from the transcripts
could be assigned to one or more codes.
Following analysis of the cognitive interviews, edits
were made to Version 1 of the instrument. In order to
document the development and refinement of each item
in the NiSCI, an item-tracking matrix was developed in-
cluding information about the development of the item,
changes made following translatability assessment,
changes following the first round of cognitive interviews,
and the final version of items (Version 2) following the
second round of interviews.
A schematic outline of the project methodology de-
scribing the steps for concept elicitation, item generation
and cognitive testing can be found in Figure 1.
Results
Literature review and clinician interviews
Results of the literature review and clinician interviews
(with five pulmonologists and a sleep expert) suggested
that to understand patients’ experience of nighttime
symptoms of COPD, it is important to evaluate their ex-
perience of COPD symptoms as well as the conse-
quences of these symptoms on sleep. The results also
informed the development of the protocol for these
studies; for example, the necessary exclusion of condi-
tions other than COPD that often result in the experi-
ence of respiratory symptoms at nighttime (e.g., sleep
apnea). Additionally, the review of literature did not
identify a PRO measure with documented evidence of
content validity that could be used to collect data on
nighttime symptoms of COPD. This suggested the need
to develop a new tool.
Description of the sample used for concept elicitation
and cognitive interviewing
Table 1 shows the sociodemographic, health status, and
clinical characteristics of the focus group and cognitive
interview participants. While the goal was for the sample
to reflect the characteristics of the study population to
be included in clinical trials, a full range of COPD sever-
ity levels (GOLD I to IV) was included to ensure suit-
ability of the content of the tool for all COPD patients.
Concept elicitation: focus group discussions
Twenty-seven patients with COPD participated in four
focus groups. Of these, twenty-four reported experien-
cing COPD symptoms at night. During each focus
Figure 1 Overview of methods.





Age, Mean (SD) 68.1 (8.7) 68.1 (6.4)
Gender, female, n (%) 14 (51.9%) 7 (70%)
Race/Ethnicity, n (%)
White 24 (88.9%) 5 (50%)
Black or African American 2 (7.4%) 5 (50%)
Native American or Alaska Native 1 (3.7%) 0 (0%)
Hispanic or Latino (not exclusive of race) 2 (7.4%) 0 (0%)
Clinical information (as reported by clinicians at recruiting sites)
GOLD stage, n (%)
I 2 (7.4%) 2 (20%)
II 15 (55.6%) 2 (20%)
III 4 (14.8%) 4 (40%)
IV 6 (22.2%) 2 (20%)
Current smoker, yes, n (%) 9 (33.3%) 2 (20%)
SGRQ-Ca, Mean (SD)
Total score 47.3 (18.6) 53.9 (16.3)
Symptom domain 57.7 (22.3) 62.9 (17.2)
Activity domain 65.9 (24.0) 76.5 (18.5)
Impact domain 33.1 (19.3) 37.5 (22.7)
HADSb, Mean (SD)
Anxiety domain 4.7 (3.3) 7.0 (3.9)
Depression domain 4.4 (2.8) 5.2 (3.7)
GOLD, Global initiative for chronic Obstructive Lung Disease; HADS, Hospital Anxiety and Depression Scale; SD, standard deviation; SGRQ-C, St. George’s
Respiratory Questionnaire for Chronic obstructive pulmonary disease.
a SGRQ-C scores range from 0 to 100, with higher scores indicating poorer health status.
b Domain scores range from 0 (no depression or anxiety) to 21; Scores of 8–10 suggest mild cases, 11–15 moderate cases, and 16 or above severe cases.
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Use of rescue inhalers X X X
Nighttime awakening (unattributed) X X X
Awakened by cough X X X
Awakened by shortness of breath X X
Awakened by wheezing X
FG, focus group.
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of the occurrence, severity, and impact of nighttime
symptoms of COPD. Nighttime symptoms reported by
the participants were shortness of breath (n = 17), cough
(n = 15), mucus/phlegm (n = 14), and wheezing (n =
11). Additionally, three participants mentioned experien-
cing chest tightness, and two mentioned chest conges-
tion. In the discussion, participants discussed the
interrelationship among the different COPD symptoms.
From their perspective, coughing, wheezing, congestion
and mucus/phlegm production were related to each
other. For example, patients described congestion being
linked to both coughing and phlegm. No new COPD
symptoms emerged in the fourth and final focus group,
suggesting saturation of concepts (Table 2).
Participants also discussed the impacts of nighttime
symptoms (Table 3). In three of the four focus groups,
participants described using inhaled rescue medication
when their nighttime symptoms of COPD were worse
than usual. Nighttime awakenings were also spontan-
eously mentioned in three of the four focus groups, with
awakening being attributed to cough, wheezing, and
shortness of breath. Some participants noted that they
experienced COPD symptoms after awakening to use
the bathroom, while others noted waking specifically
due to COPD symptoms.
Conceptual framework
The conceptual framework for the instrument was de-
veloped to depict the relationship of the various night-
time symptoms of COPD experienced by patients and
the impact of these symptoms. Concepts that were clin-
ically relevant and reported by patients, either through
spontaneous report or following probing, were included
in the conceptual framework. The clinical relevance of
concepts was confirmed by referring to findings from
the earlier clinician interviews and literature review, be-
fore finalizing the preliminary conceptual framework.Table 2 Saturation grid: nighttime symptoms reported by









Wheezing X X X
Coughing X X X X
Mucus or phlegm X X X X
Congestion X X
Shortness of breath X X X X
Tightness in chest X X
Headache X
Snoring X
Burning in chest X
FG, focus group.Item generation
Content
The conceptual framework served as a basis for generat-
ing items for the new instrument. As a result, a 16-item
instrument, the Nighttime Symptoms of COPD Instru-
ment (NiSCI), was drafted in the form of a daily diary
and included questions about the occurrence and sever-
ity of COPD symptoms, use of rescue medication at
night, and nocturnal awakenings.
During the focus groups, participants discussed their ex-
periences with specific symptoms at night. Thus, items
were generated to collect information about each of these
cardinal symptoms. Additionally, participants discussed
their symptoms in terms of severity rather than frequency,
therefore, response options were designed to cover the full
range of symptom severity rather than assess symptom
frequency. Items were not generated for other concepts
reported by participants (headache, snoring, burning
chest), as they were mentioned in only one of the four
focus groups and by fewer than two participants for each
concept. Additionally, none of these concepts were men-
tioned as being “COPD specific symptoms” in clinical
guidance documents or during clinician interviews, and
therefore, were not considered cardinal symptoms of
COPD for evaluation of patients’ experiences of COPD
symptoms at night.
As participants noted that they were woken up when
symptoms worsened and sometimes had to use rescue
medication, two items were generated: one to capture
the occurrence of nocturnal awakening due to COPD
symptoms and a second to assess the number of times
rescue medication was used. Table 4 provides examples
of patient quotes and the items that were generated
based on them. A daily diary approach was selected to
capture patient-perceived severity of symptoms and to
help patients provide accurate and timely data about
symptoms which vary from day-to-day in severity. To fa-
cilitate easier recall of nighttime experiences, the diary
was designed to be completed at the beginning of their
day. Patients were provided instructions to report on
their experiences during the time period when they
“went to bed to the time they woke up and got out of
bed to start their day.”
Table 4 Example items following elicited concepts
Concept Quotes Items
Coughing “I cannot lay down flat without coughing my head off.” You indicated that you experienced a cough last night…
“Well, I have mucous coughs, too, you know where you got
to cough up something, but most of the time it’s not the
mucous. It’s just a burning sensation right in my chest.”
- How severe was your cough?
Shortness of breath “You’re calling for a breath to fill your lungs, but you can’t
seem to get it.”
You indicated that you experienced shortness of breath
last night…
“It feels like I can’t get enough breath, and then when I get
the breath, I-I know I have a hard time trying to get rid of it.”
- How severe was your shortness of breath?
Severity of symptoms “I’m saying that I just get them or some of them I already
have that would actually get worse. Uh, maybe sometimes
I’ll have a relatively, uh, mild case of wheezing, but if I get
real infectious, uh, I’m wheezing a lot. Uh, then I’ll be coughing
a lot, so it-it’s hard to break down as to when, you know. It’s
just hard to explain.”
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incorporated on an electronic device (e.g., smart phone
or personal digital assistant [PDA] for data collection in
clinical trials).
Cognitive Interviews
To mimic the layout of the electronic device that will be
used in clinical trials, each question or set of questions
intended to appear on a single screen was presented to
the patient on a single sheet of paper. Planned skip pat-
terns for the instrument were also simulated by the
interviewer, with follow-up items being presented based
on the participants’ previous response. To ensure pa-
tients’ feedback on all of the questions in the instrument,
if an item was skipped while the participant was com-
pleting the diary as a result of the skip patterns, it was
later shown to the participant during the think-aloud
portion of the interview. This process ensured that all
patients were able to review and comment on all items,
regardless of how they completed the instrument. Four
patients were interviewed for the first stage of testing,
and revisions made based on feedback from patients
during this stage were tested with six additional patients.
Participants demonstrated an understanding of all in-
structions and items as intended, and expressed that no
aspect of their experience of COPD symptoms at night
were missing. Participants reported that they were able
to recall their experiences of the previous night as they
responded to each item, selecting the response that best
represented their experiences. Cognitive interviews sup-
ported evidence of patient understanding of the response
options.
In the first stage of testing, feedback from two partici-
pants suggested that further clarification regarding the
recall period should be added to the instructions and
definitions be explained to patients during patient train-
ing. However, timeframe to which the instructionsreferred (the previous night) was generally understood.
Based on this feedback, additional clarifications were
added to the instructions and it was noted that the
timeframe should be stressed during site and patient
training.
There was one minor revision made to an item’s re-
sponse choices following the second stage of interviews
to create Version 2 of the instrument: question marks
after the symptoms listed in an item were removed for
improved clarity on the screen of an electronic device.
Discussion
This manuscript outlines the development of the NiSCI,
an instrument to measure nighttime symptoms of
COPD, and documents evidence of its content validity.
This instrument is intended for future use in clinical tri-
als to collect data to support label claims related to im-
provements in nighttime symptoms of COPD.
Consistent with the methods [13,14] required to en-
sure the content validity of PRO tools used to collect
data to support claims [12], the development of the
NiSCI was based on concept elicitation with patients.
Patient understanding of the instrument was tested
using cognitive interviewing. The conceptual framework
for the instrument was based on concept elicitation from
patients about their experiences of nighttime symptoms
of COPD, with clinical validity ensured by referring back
to initial information learned from the literature and
clinician interviews.
Item development was guided by the conceptual frame-
work and particular attention was paid to the incorpor-
ation of the terminology used by patients. Finally, cognitive
interviews with patients following completion of the meas-
ure provided evidence that participants interpreted the
items, instructions, and response options as intended, and
that the items comprehensively evaluated patient experi-
ences of nighttime symptoms of COPD.
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COPD experience specific symptoms at night, and that
the severity of these symptoms is variable across nights.
The symptoms that patients described at night were
consistent with the cardinal symptoms outlined in the
COPD treatment guidelines (e.g., cough, sputum pro-
duction [mucus and phlegm], shortness of breath) [22]
and other symptoms known to be associated with COPD
such as wheezing and chest tightness [22]. Additionally,
the symptoms described by patients during the qualita-
tive work were consistent with those reported by the cli-
nicians interviewed for this study.
Patients noted throughout the discussions that their
COPD symptoms often caused them to wake up during
the night. They were able to report nocturnal awakening
resulting from the experience of COPD symptoms as
distinct from awakening for other reasons (e.g., to go to
the bathroom). Research studies in COPD have linked
sleep disturbances to negative outcomes, underscoring
the importance of both measuring and reducing sleep
disturbance [4]. However, in spite of the importance of
sleep disturbances on patients’ well-being, to date night-
time awakenings have been infrequently studied as an
endpoint in trials evaluating COPD treatments [6-10].
Focus group participants also discussed the need to
use rescue medication when their nighttime symptoms
increased in severity. This is consistent with the clinician
interviews conducted for this study as well as COPD tri-
als to date, as rescue medication use has often been used
as an endpoint in clinical trials of products evaluated for
the management of respiratory diseases [10,11].
The methods used for concept elicitation and cognitive
interviewing closely followed the requirements for gen-
erating evidence of content validity for PRO tools, to be
used to collect data to support label claims [12].
Though the sample sizes for the focus groups and in-
terviews were small, the results showed evidence of sat-
uration of concepts. A limitation of the concept
elicitation work was that despite attempts to recruit a di-
verse group of patients, the final sample was not as di-
verse as intended, particularly in terms of race and
ethnicity. More racial diversity was present in the sample
of participants in the cognitive interviews. Subsequent
testing of the instrument will also seek to include a di-
verse sample that represents the COPD population in
the United States.
Conclusions
Previous studies have demonstrated the importance of
nighttime symptoms of COPD on various aspects of pa-
tients’ lives [2-4]; however there is currently no standard-
ized way to measure these symptoms in clinical studies to
examine potential treatment benefit. This study docu-
ments evidence of content validity for the NiSCI, a newPRO instrument to evaluate COPD nighttime symptoms.
Future research will involve item reduction, evaluation of
the instrument’s psychometric properties, and exploration
of additional impacts of nighttime symptoms of COPD.
Our goal is to convert the instrument to an electronic for-
mat and determine usability of the electronic version for
clinical trials. Consistent with the methodological require-
ments to ensure content validity, the current conceptual
framework will continue to be updated once item reduc-
tion and validation analyses are complete.
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